Mitochondrial dysfunction, not faulty genes, may sit at the root of cancer and mental illness

Thomas Seyfried, a cancer researcher whose work sits well outside the oncology mainstream, makes a blunt claim: the origin of cancer resides in the organelle called the mitochondria. What gives that claim traction is the consistency of the underlying observation. Every cancer cell his team has examined shows defects in the number, structure, and function of that organelle. In many cases, the internal architecture is simply absent. As Seyfried describes it, what remains are “ghost mitochondria,” shells with nothing inside, or with whatever is inside badly deformed.

The genetic story, by contrast, has a structural weakness that the evidence keeps surfacing. Seyfried notes that none of the mutations associated with cancer are 100 percent penetrant, which means they function as secondary risk factors rather than root causes. The mutation framework is not wrong, but it appears to be downstream of something else.

That something else, in Seyfried’s account, is metabolic collapse at the mitochondrial level. Intermittent hypoxia damages the efficiency of oxidative phosphorylation, forcing cells into compensatory fermentation. The cancer cell that results cannot switch to fatty acids or ketone bodies for fuel because its mitochondria are too damaged to handle them. It depends on glucose and glutamine. Seyfried adds that some oncologists are already drawing a practical conclusion from this, using ketogenic diet and fasting protocols to protect healthy cells and sensitize tumors before administering lower, more targeted doses of chemotherapy.

Martin Picard, a researcher at the intersection of mitochondrial biology and behavior, extends the metabolic framing toward psychiatry. His observation is direct: injecting people with lactate, a signal of energetic stress, can trigger panic attacks. Elevated levels of GDF-15, a marker associated with energetic stress, predict higher rates of bipolar disease, depression, and schizophrenia. The implication is that at least some mental illness represents a failure of cellular energy management rather than, or in addition to, a disorder of neurotransmitter signaling. Picard also notes that the cancer community has itself begun to shift, with an emerging perspective that changes in metabolism and in the way electrons flow through mitochondrial circuitry can drive the genesis of a new cancer cell.

We've not been able to discover a single psychiatric condition in which sleep is normal. Matt Walker

Sleep research adds a complementary layer. Matt Walker, a neuroscientist who studies sleep, notes that no psychiatric condition has yet been identified in which sleep is normal. That pattern does not establish causation, but it suggests a shared biological substrate beneath conditions that clinical psychiatry has historically treated as distinct. Disrupted sleep, disrupted metabolism, and disrupted mitochondrial function may be different readings of the same underlying failure.

David Sinclair, whose research concerns aging, connects the cancer and aging questions directly. Aging metabolism, he argues, moves toward a state that resembles cancer cell metabolism. The implication runs in both directions: aged biology becomes more hospitable to cancer, and cancer itself may be understood as a form of accelerated cellular aging. Sinclair adds that a majority of cancers grown in the lab will shrink and die in animal models if researchers attempt to reverse the cells’ age. That finding does not translate directly to clinical treatment, but it supports the idea that cellular age state and cancer state are not as separate as the genetic paradigm assumed.

Tim Ferriss, approaching Alzheimer’s disease from a different angle, offers a parallel dissent from the dominant amyloid hypothesis, attributing much of what is labeled Alzheimer’s to vascular dementia and mitochondrial dysfunction. That framing is one observer’s reading rather than a controlled research finding, but it echoes the broader pattern: conditions long explained through a single molecular villain, whether amyloid or a mutated gene, may have more fundamental metabolic roots.

What connects these accounts is not a unified theory. Seyfried’s claims about cancer are far more developed and specific than Ferriss’s comments on dementia. Picard’s work on GDF-15 is suggestive rather than conclusive. But the direction is consistent enough to matter. If mitochondrial function sits closer to the origin of cancer, aging, and certain psychiatric conditions than gene-centric models assumed, the research agenda and the treatment toolkit that follow from those models will require substantial revision. The field has not settled the question. It has, however, reopened it.